AF
VIR icon

Amalgamated Financial’s Vir Biotechnology VIR Stock Holding History

Amalgamated Financial’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$252K Buy
+9,803
New +$291K ﹤0.01% 1807

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.44B AUM 23.16% 1-Year Est. Return

Amalgamated Financial's VIR Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Vir Biotechnology (VIR) in Q1 2022: 9,803 shares worth $252K. The stake represents ﹤0.01% of the portfolio and ranks #1807 among its holdings.

204 funds tracked by Wall St. Rank hold VIR as of Q1 2022.

  • Amalgamated Financial held 9,803 shares of Vir Biotechnology worth $252K as of Q1 2022.
  • Vir Biotechnology was a new Amalgamated Financial position in Q1 2022.
  • Vir Biotechnology made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1807 holding.
  • 204 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.